Gilead Sciences Inc. (GILD) has gapped open sharply higher Thursday morning and is now up 4.07 at $57.70. The stock has broken out past resistance and has set a new high for the year.
Bristol-Myers Squibb (BMY) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
For comments and feedback: editorial@rttnews.com